Literature DB >> 7561680

Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15.

R A Seder1, K H Grabstein, J A Berzofsky, J F McDyer.   

Abstract

Cytokines have been shown to be powerful regulators of the immune response. In this study, we analyze the effect that the newly recognized cytokine interleukin (IL)-15 has on proliferation and cytokine induction using peripheral blood mononuclear cells (PBMCs) and purified CD4+ T cells from patients infected with human immunodeficiency virus (HIV) who are at various stages in their disease. We observed that IL-15 enhances the proliferative response in a dose-dependent manner from PBMCs of HIV-infected individuals when stimulated by polyclonal mitogen, tetanus toxoid, or HIV-specific antigen. The effects of exogenous IL-15 are substantially diminished by adding a neutralizing antibody to the beta chain of the IL-2 receptor. Moreover, the ability of IL-15 to increase proliferation is enhanced by the presence of endogenous IL-2 produced in the cultures. The effect that exogenous IL-15 had on IL-2, IL-4, and interferon (IFN)-gamma induction from PBMC's or CD4+ T cells in response to mitogen or tetanus toxoid was also examined. This was compared to the effect that exogenous IL-2 and IL-12 had under the same conditions. Addition of IL-2 or IL-15 to short-term in vitro cultures of either PBMCs or CD4+ T cells had little effect on IL-2, IL-4, or IFN-gamma production. By contrast, IL-12 caused substantial enhancement of both IL-2 and IFN-gamma production from these cultures. The role that endogenous cytokines have on IFN-gamma induction was also studied. Addition of a neutralizing antibody to the alpha chain of the IL-2 receptor or IL-12 to antigen stimulated cultures caused a striking decrease in IFN-gamma production. Neutralization of endogenous IL-15 also resulted in diminished IFN-gamma production from cultures stimulated with mitogen. IL-4 and IFN-gamma protein production by PBMCs and CD4+ T cells stimulated with mitogen was assessed to see if we could detect a specific bias of cytokine production. Small amounts of IL-4 were detected from CD4+ T cells but not PBMCs from most individuals tested. IFN-gamma and IL-2, however, were also produced from these same cultures. These results further elucidate the mechanism of cytokine regulation in HIV-infected individuals, and they provide evidence that IL-15 may be a useful immune modulator.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561680      PMCID: PMC2192305          DOI: 10.1084/jem.182.4.1067

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition.

Authors:  H C Lane; J M Depper; W C Greene; G Whalen; T A Waldmann; A S Fauci
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

Review 3.  Immunopathogenesis of the acquired immunodeficiency syndrome.

Authors:  D L Bowen; H C Lane; A S Fauci
Journal:  Ann Intern Med       Date:  1985-11       Impact factor: 25.391

4.  Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS.

Authors:  J D Lifson; C J Benike; D F Mark; K Koths; E G Engleman
Journal:  Lancet       Date:  1984-03-31       Impact factor: 79.321

5.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

6.  Depressed interleukin 2 receptor expression in acquired immune deficiency and lymphadenopathy syndromes.

Authors:  H E Prince; V Kermani-Arab; J L Fahey
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

Review 7.  Immunologic abnormalities in the acquired immunodeficiency syndrome.

Authors:  H C Lane; A S Fauci
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

8.  Interleukin-2 production and response to exogenous interleukin-2 in a patient with the acquired immune deficiency syndrome (AIDS).

Authors:  G J Hauser; T Bino; H Rosenberg; V Zakuth; E Geller; Z Spirer
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

9.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

10.  IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma.

Authors:  P Zhou; M C Sieve; J Bennett; K J Kwon-Chung; R P Tewari; R T Gazzinelli; A Sher; R A Seder
Journal:  J Immunol       Date:  1995-07-15       Impact factor: 5.422

View more
  24 in total

1.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

2.  Activation of antigen-induced lymphocyte proliferation by interleukin-15 without the mitogenic effect of interleukin-2 that may induce human immunodeficiency virus-1 expression.

Authors:  A H Patki; M E Quiñones-Mateu; D Dorazio; B Yen-Lieberman; W H Boom; E K Thomas; M M Lederman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

4.  Regulation of lck degradation and refractory state in CD8+ cytotoxic T lymphocytes.

Authors:  Michael Uhlin; Maria G Masucci; Victor Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-15       Impact factor: 11.205

5.  Induction of HIV-1 replication by type 1-like cytokines, interleukin (IL)-12 and IL-15: effect on viral transcriptional activation, cellular proliferation, and endogenous cytokine production.

Authors:  L Al-Harthi; K A Roebuck; A Landay
Journal:  J Clin Immunol       Date:  1998-03       Impact factor: 8.317

Review 6.  Immune dysregulation and CD4+ T cell loss in HIV-1 infection.

Authors:  L Meyaard; F Miedema
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Differential effects of interleukin-12, interleukin-15, and interleukin-2 on human immunodeficiency virus type 1 replication in vitro.

Authors:  M Bayard-McNeeley; H Doo; S He; A Hafner; W D Johnson; J L Ho
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

8.  Interleukin-15 increases effector memory CD8+ t cells and NK Cells in simian immunodeficiency virus-infected macaques.

Authors:  Yvonne M Mueller; Constantinos Petrovas; Paul M Bojczuk; Ioannis D Dimitriou; Brigitte Beer; Peter Silvera; Francois Villinger; J Scott Cairns; Edward J Gracely; Mark G Lewis; Peter D Katsikis
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

9.  Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease.

Authors:  S F Sieg; D A Bazdar; C V Harding; M M Lederman
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.

Authors:  G d'Ettorre; G Forcina; M Andreotti; L Sarmati; L Palmisano; M Andreoni; S Vella; C M Mastroianni; V Vullo
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.